New technology detects changes in the brain beyond the lesions seen with normal MRI scans.
Since its inception, magnetic resonance imaging (MRI) has been lauded for its ultra-sensitivity in identifying plaques in the brain and spine of patients with multiple sclerosis (MS). In the years since, it has become vital for diagnosing MS, in addition to gauging response to treatment or disease progression.
But despite the capabilities of standard MRI — equipped with conventional 1.5-, or 3-tesla (T) magnetic field strength — the technology isn't sensitive enough to detect all the components of this neurodegenerative disease in which the body's immune system attacks the fatty protective myelin sheath surrounding nerve fibers.
Now, a new study published online Jan. 4 in the journal Radiology found that high-resolution MRI of neurochemicals termed MR spectroscopic imaging at 7.0 T can help visualize pathologic findings beyond the lesions in participants with multiple sclerosis. It detected MS-relevant neurochemical changes in the normal-appearing white matter and cortical gray matter of the brain that were associated with patients' disability.
The research was led by Eva Heckova, Ph.D., a postdoctoral researcher in the High Field MRCentre at the Medical University of Vienna in Austria.
"If the results are confirmed in further clinical longitudinal studies, MR spectroscopic imaging could become a standard imaging tool for initial diagnosis, for disease progression and therapy monitoring," Heckova says.
MR spectropic imaging allows for assessment of brain metabolism and is of keen interest in MS, where MRI showing merely structure cannot adequately shed light on microscopic components of disease activity.
The study recruited 65 participants with MS and 20 age- and sex-matched healthy controls, with an average age of 32, between January 2016 and December 2017. Metabolic ratios were obtained in white matter lesions, normal-appearing white matter and cortical gray matter regions.
MR spectroscopic imaging at 7.0 T permitted visualization of brain metabolic alterations, particularly those related to neuroinflammation, which cannot be visible with conventional T1- or T2-weighted MRI.
“Seven-tesla MR spectroscopy offers improved signal-to-noise ratios and improved spectral resolution compared with lower field strengths, such as 3.0 and 1.5T,” Peter B. Barker, D.Phil., professor of radiology and oncology at the Johns Hopkins University School of Medicine in Baltimore, wrote in an editorial accompanying the trial’s results. “As a result, more compounds can be detected with higher accuracy. However, before these improvements can be realized in practice, many engineering challenges have to be overcome ...”
The National Multiple Sclerosis Society expressed optimism that this trial could pave the way toward better diagnostic tools. "We find this research finding to be intriguing and encourage the research team to continue to explore the utility of this approach in the diagnosis of MS,” says Julie Fiol, the society's associate vice president for healthcare access.
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More
2 Commerce Drive
Cranbury, NJ 08512